Tenaya Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company committed to discovering, developing, and delivering potentially curative therapies for heart disease. Founded in 2016 and headquartered in South San Francisco, California, the company leverages three distinct but interrelated product platforms—Gene Therapy, Cellular Regeneration, and Precision Medicine—to target both rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya's clinical-stage pipeline is led by two adeno-associated virus (AAV)-based gene therapy candidates: TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Additionally, the company is advancing TN-301, a highly selective small-molecule HDAC6 inhibitor, for heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD) models.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Leveraging proprietary integrated capabilities, including human induced pluripotent stem cell-derived cardiomyocytes (iPSC-derived cardiomyocytes), engineered heart tissue models, and machine learning algorithms to identify and validate novel genetic targets for heart disease.
Expected impact: Enables modality-agnostic target validation and expands the pipeline of genetic medicines for both rare and prevalent cardiovascular conditions.
Developing scalable, high-yield AAV manufacturing platforms (such as HEK293 and Sf9 insect cell lines) at the company's proprietary manufacturing center to support clinical translation and future commercialization.
Expected impact: Optimizes gene dosing, safety, and cost-efficiency while reducing reliance on third-party contract manufacturers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Pairs Tenaya's target identification and validation platform with Alnylam's leadership in RNA interference (RNAi) therapeutics to discover and validate up to 15 novel genetic targets for cardiovascular diseases.
Terms: Tenaya received a $10.0 million upfront payment in April 2026, along with reimbursement for research costs over a two-year validation term. Tenaya is eligible to receive up to $1.13 billion in development and commercial milestone payments, plus potential royalties.